|
|
|
Dermatology Times will be reporting from the AAD annual meeting this week in San Diego. Visit our conference news page to follow the developments from the meeting. |
|
|
|
|
The experts weigh in on pros and cons of biologics
|
|
Access issues due to cost and availability causes disparities in biologics use; cancer risk is minimal and there is much more on the horizon for hidradenitis suppurativa, researchers say at AAD 2018. |
|
Learn More.
|
|
|
|
Switching biologic treatments in dermatology
|
|
Not all biologic treatments are equal. Side effects, effectiveness, cost and administration style are among factors physicians should consider when switching treatments, experts report at AAD 2018. |
|
Learn More.
|
|
ADVERTISEMENT
|
|
|
|
|
|
Managing hedgehog therapies for basal cell carcinoma
|
|
While the vast majority of basal cell carcinomas are treated and resolved with surgery, systemic therapy with one of the two hedgehog pathway inhibitors could be a treatment option for unresectable or metastasized disease, researchers reported at the American Academy of Dermatology annual meeting in San Diego this week. |
|
Learn More.
|
|
ADVERTISEMENT
|
|
|
|
|
|
ADVERTISEMENT
|
| Show Your Unexpected. Spray on SERNIVO. |
SERNIVO® (betamethasone dipropionate) Spray, 0.05% features a novel lotion-like spray formulation with a balance of high penetration/permeation and low systemic absorption.
 Learn more
|
|
